Reduction in Nesfatin-1 Levels in the Cerebrospinal Fluid and Increased Nigrostriatal Degeneration Following Ventricular Administration of Anti-nesfatin-1 Antibody in Mice

Overview

Journal Front Neurosci

Date 2021 Feb 22

PMID 33613183

Citations 5

Authors

Huanhuan Chen

Xuelian Li

Hui Ma

Wei Zheng

Xiaoli Shen

Affiliations

Soon will be listed here.

Abstract

Nesfatin-1 is one of several brain-gut peptides that have a close relationship with the central dopaminergic system. Our previous studies have shown that nesfatin-1 is capable of protecting nigral dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. A recent study also revealed a reduced blood level of nesfatin-1 in patients with Parkinson's disease (PD). The current study was designed to investigate whether reduced nesfatin-1 in cerebrospinal fluid (CSF) induces nigrostriatal system degeneration. An intra-cerebroventricular (ICV) injection technique was used to administer anti-nesfatin-1 antibody directly into the lateral ventricle of the brain. Enzyme-linked immunosorbent assay (ELISA) results showed that ICV injection of anti-nesfatin-1 antibody into the lateral ventricle of the brain once daily for 2 weeks caused a significant reduction in nesfatin-1 levels in the CSF (93.1%). Treatment with anti-nesfatin-1 antibody resulted in a substantial loss (23%) of TH-positive (TH+) dopaminergic neurons in the substantia nigra pars compacta (SNpc), as shown by immunofluorescence staining, a depletion in dopamine and its metabolites in the striatum detected by high-performance liquid chromatography (HPLC), and obvious nuclear shrinkage and mitochondrial lesions in dopaminergic neurons in the SNpc detected by transmission electron microscopy (TEM). Furthermore, the results from our Western blot and ELISA experiments demonstrated that anti-nesfatin-1 antibody injection induced an upregulation of caspase-3 activation, increased the expression of -ERK, and elevated brain-derived neurotrophic factor (BDNF) levels in the SNpc. Taken together, these observations suggest that reduced nesfatin-1 in the brain may induce nigrostriatal dopaminergic system degeneration; this effect may be mediated mitochondrial dysfunction-related apoptosis. Our data support a role of nesfatin-1 in maintaining the normal physiological function of the nigrostriatal dopaminergic system.

Citing Articles

Nesfatin-1: A Novel Diagnostic and Prognostic Biomarker in Digestive Diseases.

Damian-Buda A, Matei D, Ciobanu L, Damian-Buda D, Pop R, Buzoianu A Biomedicines. 2024; 12(8).

PMID: 39200377 PMC: 11352118. DOI: 10.3390/biomedicines12081913.

Nesfatin-1: A Biomarker and Potential Therapeutic Target in Neurological Disorders.

Zhou S, Nao J Neurochem Res. 2023; 49(1):38-51.

PMID: 37740893 DOI: 10.1007/s11064-023-04037-0.

Demystifying the Neuroprotective Role of Neuropeptides in Parkinson's Disease: A Newfangled and Eloquent Therapeutic Perspective.

Behl T, Madaan P, Sehgal A, Singh S, Makeen H, Albratty M Int J Mol Sci. 2022; 23(9).

PMID: 35562956 PMC: 9099669. DOI: 10.3390/ijms23094565.

"Sibling" battle or harmony: crosstalk between nesfatin-1 and ghrelin.

Chen X, Dong J, Jiao Q, Du X, Bi M, Jiang H Cell Mol Life Sci. 2022; 79(3):169.

PMID: 35239020 PMC: 11072372. DOI: 10.1007/s00018-022-04193-6.

Effects of subanesthetic intravenous ketamine infusion on neuroplasticity-related proteins in male and female Sprague-Dawley rats.

Zhang M, Spencer H, Berman R, Radford K, Choi K IBRO Neurosci Rep. 2021; 11:42-51.

PMID: 34286313 PMC: 8273220. DOI: 10.1016/j.ibneur.2021.06.005.

References

Tang C, Fu X, Xu X, Wei X, Pan H . The anti-inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides. 2012; 36(1):39-45. DOI: 10.1016/j.peptides.2012.04.014. View

Daubner S, Le T, Wang S . Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys. 2010; 508(1):1-12. PMC: 3065393. DOI: 10.1016/j.abb.2010.12.017. View

Emir G, Unal Y, Yilmaz N, Tosun K, Kutlu G . The association of low levels of nesfatin-1 and glucagon-like peptide-1 with oxidative stress in Parkinson's disease. Neurol Sci. 2019; 40(12):2529-2535. DOI: 10.1007/s10072-019-03975-4. View

Blanchard V, Raisman-Vozari R, Savasta M, Hirsch E, Feuerstein C, Agid Y . Cellular quantification of tyrosine hydroxylase in the rat brain by immunoautoradiography. J Neurochem. 1993; 61(2):617-26. DOI: 10.1111/j.1471-4159.1993.tb02166.x. View

de Lau L, Breteler M . Epidemiology of Parkinson's disease. Lancet Neurol. 2006; 5(6):525-35. DOI: 10.1016/S1474-4422(06)70471-9. View

Perier C, Bove J, Vila M . Mitochondria and programmed cell death in Parkinson's disease: apoptosis and beyond. Antioxid Redox Signal. 2011; 16(9):883-95. DOI: 10.1089/ars.2011.4074. View

Clynen E, Swijsen A, Raijmakers M, Hoogland G, Rigo J . Neuropeptides as targets for the development of anticonvulsant drugs. Mol Neurobiol. 2014; 50(2):626-46. PMC: 4182642. DOI: 10.1007/s12035-014-8669-x. View

Dawson T, Dawson V . Molecular pathways of neurodegeneration in Parkinson's disease. Science. 2003; 302(5646):819-22. DOI: 10.1126/science.1087753. View

Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti L . A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Sci Rep. 2015; 5:17989. PMC: 4675070. DOI: 10.1038/srep17989. View

10.

Dore R, Levata L, Gachkar S, Johren O, Mittag J, Lehnert H . The thermogenic effect of nesfatin-1 requires recruitment of the melanocortin system. J Endocrinol. 2017; 235(2):111-122. DOI: 10.1530/JOE-17-0151. View

11.

Larsen S, Hanss Z, Kruger R . The genetic architecture of mitochondrial dysfunction in Parkinson's disease. Cell Tissue Res. 2018; 373(1):21-37. PMC: 6015629. DOI: 10.1007/s00441-017-2768-8. View

12.

Stanciu M, DeFranco D . Prolonged nuclear retention of activated extracellular signal-regulated protein kinase promotes cell death generated by oxidative toxicity or proteasome inhibition in a neuronal cell line. J Biol Chem. 2001; 277(6):4010-7. DOI: 10.1074/jbc.M104479200. View

13.

Chen S, Wu C, Hwang W, Yang D . More Insight into BDNF against Neurodegeneration: Anti-Apoptosis, Anti-Oxidation, and Suppression of Autophagy. Int J Mol Sci. 2017; 18(3). PMC: 5372561. DOI: 10.3390/ijms18030545. View

14.

Pickrell A, Huang C, Kennedy S, Ordureau A, Sideris D, Hoekstra J . Endogenous Parkin Preserves Dopaminergic Substantia Nigral Neurons following Mitochondrial DNA Mutagenic Stress. Neuron. 2015; 87(2):371-81. PMC: 4803114. DOI: 10.1016/j.neuron.2015.06.034. View

15.

Evans C, Thomas R, Freeman T, Hvoslef-Eide M, Good M, Kidd E . Selective reduction of APP-BACE1 activity improves memory via NMDA-NR2B receptor-mediated mechanisms in aged PDAPP mice. Neurobiol Aging. 2018; 75:136-149. PMC: 6357873. DOI: 10.1016/j.neurobiolaging.2018.11.011. View

16.

Gilmozzi V, Gentile G, Castelo Rueda M, Hicks A, Pramstaller P, Zanon A . Interaction of Alpha-Synuclein With Lipids: Mitochondrial Cardiolipin as a Critical Player in the Pathogenesis of Parkinson's Disease. Front Neurosci. 2020; 14:578993. PMC: 7573567. DOI: 10.3389/fnins.2020.578993. View

17.

Jiang Q, Gu Z, Zhang G, Jing G . Diphosphorylation and involvement of extracellular signal-regulated kinases (ERK1/2) in glutamate-induced apoptotic-like death in cultured rat cortical neurons. Brain Res. 2000; 857(1-2):71-7. DOI: 10.1016/s0006-8993(99)02364-1. View

18.

Klockgether T . Parkinson's disease: clinical aspects. Cell Tissue Res. 2004; 318(1):115-20. DOI: 10.1007/s00441-004-0975-6. View

19.

Wu C, Chen S, Yin J, Hwang C, Yang D . Nuclear Factor-kappaB-Dependent Sestrin2 Induction Mediates the Antioxidant Effects of BDNF Against Mitochondrial Inhibition in Rat Cortical Neurons. Mol Neurobiol. 2015; 53(6):4126-4142. DOI: 10.1007/s12035-015-9357-1. View

20.

Weibert E, Hofmann T, Stengel A . Role of nesfatin-1 in anxiety, depression and the response to stress. Psychoneuroendocrinology. 2018; 100:58-66. DOI: 10.1016/j.psyneuen.2018.09.037. View